Diligence Reports. Within thirty (30) days after the end of each calendar year, Licensee shall report in writing to BIDMC on progress made toward the due diligence obligations set forth in Section 3.1 during such preceding 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 3 contracts
Samples: Exclusive License Agreement (Acceleron Pharma Inc), Exclusive License Agreement (Acceleron Pharma Inc), Exclusive License Agreement (Acceleron Pharma Inc)
Diligence Reports. Within thirty sixty (3060) days after the end of each calendar year, Licensee LICENSEE shall report in writing to BIDMC LICENSOR on progress made toward the due diligence obligations objectives set forth in Section 3.1 during such preceding 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 2 contracts
Samples: Non Exclusive License Agreement (Neurokine Pharmaceuticals Inc.), Non Exclusive License Agreement (Neurokine Pharmaceuticals Inc.)